The safer effector cell? Potential of CD147 CAR NK cells to tackle tumors with lower toxicity
Year: 2025
Type: article
Abstract: In a recent issue of Molecular Therapy: Oncology, Saha et al. explore the potential advantages in safety of chimeric antigen receptor (CAR) natural killer (NK) cells over CAR T cells with maintained anti-tumor efficacy.1 Through the use of CD147-CAR-NK cells in the context of hepatocellular carcinoma models, the article aims to evaluate the toxicity profile of CAR-NK cells in isolation and compared to CD147-CAR-T cell therapy. The key findings indicate that CD147-CAR-NK cells exhibit selective “on-target, on-tumor” activity, a favorable “on-target, off-tumor” safety profile, and when compared with CD147-CAR-T cells, reduced neurotoxicity.
Source: Molecular Therapy Oncology
Authors: Alan Hodges, Shu-Hsia Chen, Ping-Ying Pan
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,900
Awards: LILRB modulates tumor microenvironment and promotes tumor progression, Modulation of tumor inflammatory factor for immune therapy, Mechanism of Intratumoral Transport of Particulate Drugs, Novel gene delivery to modulate the tumor microenvironment and antigen-specific antitumor immunity, SPORE in Lymphoma
OpenAlex ID: W4411036545